Pacific Biosciences Of California (PACB) Notes Payables (2011 - 2022)

Pacific Biosciences Of California's Notes Payables history runs 7 years deep, the most recent figure standing at $1.8 million for Q4 2022.

• On a quarterly basis, Notes Payables rose 14.55% year-over-year to $1.8 million in Q4 2022; TTM through Dec 2022 was $1.8 million, a 14.55% increase from a year earlier, with the FY2022 full-year figure at $1.8 million, up 14.55% from the prior year.
• Notes Payables improved to $1.8 million in Q4 2022 per PACB's latest filing, from $1.6 million in the prior quarter.
• Across five years, Notes Payables topped out at $15.9 million in Q4 2019 and bottomed at $1.6 million in Q4 2021.
• The 3-year median for Notes Payables is $15.1 million (2019), against an average of $10.8 million.
• Biggest YoY gain for Notes Payables was 14.55% in 2022; the steepest drop was 14.55% in 2022.
• Year by year, Notes Payables stood at $15.9 million in 2019, then plunged by 89.87% to $1.6 million in 2021, then gained by 14.55% to $1.8 million in 2022.
• Per Business Quant, the three latest PACB Notes Payables figures stand at $1.8 million (Q4 2022), $1.6 million (Q4 2021), and $15.9 million (Q4 2019).